MCID: UVT001
MIFTS: 57

Uveitis

Categories: Eye diseases, Immune diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Uveitis

MalaCards integrated aliases for Uveitis:

Name: Uveitis 12 74 58 29 54 43 15 39 17 71

Classifications:

Orphanet: 58  
Rare eye diseases


External Ids:

Disease Ontology 12 DOID:13141
MeSH 43 D014605
NCIt 49 C26909
SNOMED-CT 67 128473001
ICD10 32 H20.9
MESH via Orphanet 44 D014605
UMLS via Orphanet 72 C0042164
Orphanet 58 ORPHA98715
UMLS 71 C0042164

Summaries for Uveitis

Disease Ontology : 12 An uveal disease is characterized by inflammation of any of the layers of the uvea of the eye, which includes the iris, ciliary body, and choroid.

MalaCards based summary : Uveitis is related to intermediate uveitis and fuchs' heterochromic uveitis. An important gene associated with Uveitis is NOD2 (Nucleotide Binding Oligomerization Domain Containing 2), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs tannic acid and Benzocaine have been mentioned in the context of this disorder. Affiliated tissues include eye, t cells and endothelial, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Wikipedia : 74 Uveitis is the inflammation of the uvea, the pigmented layer that lies between the inner retina and the... more...

Related Diseases for Uveitis

Diseases in the Uveitis family:

Autoimmune Uveitis Posterior Uveitis
Intermediate Uveitis Infectious Anterior Uveitis
Infectious Posterior Uveitis Systemic Diseases with Anterior Uveitis
Systemic Diseases with Posterior Uveitis

Diseases related to Uveitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1107)
# Related Disease Score Top Affiliating Genes
1 intermediate uveitis 34.8 TNF IL2RA IL10 IFNG HLA-B
2 fuchs' heterochromic uveitis 34.6 TGFB2 IFNG
3 posterior uveitis 34.5 TNF SAG RBP3 IL4 IL2RA IFNG
4 blau syndrome 34.2 TNF NOD2 IL4 IL10
5 iridocyclitis 34.1 TNF RBP3 IL17A IL10 HLA-B
6 pars planitis 34.0 RBP3 IL1R1 HLA-B HLA-A
7 panuveitis 33.6 TNF SAG RBP3 IL17A IL10 IFNA2
8 birdshot chorioretinopathy 33.5 RBP3 IL17A HLA-A
9 multifocal choroiditis 33.2 TNF IL10
10 retinal vasculitis 33.2 TNF SAG RBP3 CCL2
11 iritis 33.2 TNF RBP3 NOD2 IL17A HLA-B
12 sympathetic ophthalmia 33.0 TNF RBP3 IL10 ICAM1 CTLA4
13 vitreoretinopathy, neovascular inflammatory 33.0 TGFB2 CRYAA CCL2 CAPN5
14 macular retinal edema 32.9 TNF ICAM1 CRYAA CCL2
15 spondyloarthropathy 1 32.9 TNF NOD2 IL1R1 IL17A HLA-B
16 tropical spastic paraparesis 32.9 IL2RA IL17A IL10 IFNG
17 choroiditis 32.8 TNF SAG RBP3 IL17A IL10 IFNG
18 chorioretinitis 32.8 TNF SAG RBP3 IL17A IL10 IFNG
19 severe cutaneous adverse reaction 32.8 TNF HLA-B HLA-A CTLA4
20 autoimmune lymphoproliferative syndrome 32.6 TNF IL2RA IL10 CTLA4
21 autoimmune uveitis 32.6 TRIB2 TNF TGFB2 SAG RBP3 IL4
22 vogt-koyanagi-harada disease 32.6 IL2RA IL17A IL10 IFNG IFNA2 HLA-B
23 juvenile rheumatoid arthritis 32.5 TNF IL2RA IL1R1 IL10 IFNG CTLA4
24 juvenile arthritis 32.1 IL1R1 IL10 HLA-A
25 spondylitis 31.8 TNF NOD2 IL17A IL10 IFNG HLA-B
26 toxoplasmosis 31.8 TNF IL4 IL10 IFNG
27 syphilis 31.8 TNF IL17A IFNG
28 sarcoidosis 1 31.8 TNF NOD2 IL2RA IFNG ICAM1 HLA-A
29 hypopyon 31.7 TNF RBP3 IL17A IL10 HLA-B
30 cytomegalovirus retinitis 31.6 TNF IL10 IFNG HLA-B HLA-A
31 retinal detachment 31.6 TNF TGFB2 IL10 IFNG CCL2 CAPN5
32 endophthalmitis 31.4 TNF SAG ICAM1 CRYAA
33 ocular toxoplasmosis 31.4 NOD2 IL17A
34 optic neuritis 31.4 TNF IL2RA IL10
35 keratopathy 31.4 TNF TGFB2 IL4 ICAM1
36 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 31.4 IL17A IL10 IFNG CTLA4
37 chickenpox 31.3 TNF IL4 IL10 IFNG CTLA4
38 exanthem 31.3 TNF IL10 IFNG CTLA4
39 neuritis 31.3 TNF IL4 IL10 IFNG CCL2
40 scleritis 31.3 TNF IL4 IFNG CTLA4 CCL2
41 reactive arthritis 31.2 TNF IL17A IL10 IFNG HLA-B
42 herpes zoster 31.2 TNF IL10 IFNG IFNA2 HLA-B HLA-A
43 neurosyphilis 31.2 IL17A IL10
44 behcet syndrome 31.1 TNF SAG RBP3 NOD2 IL4 IL2RA
45 vasculitis 31.1 TNF IL17A IL10 IFNA2 ICAM1 HLA-B
46 keratitis, hereditary 31.1 TNF IL17A CRYAA
47 retinal vascular disease 31.1 TNF ICAM1 CRYAA CCL2
48 histiocytosis 31.1 TNF IL17A IFNG
49 crohn's colitis 31.1 TNF NOD2 IFNG
50 histoplasmosis 31.0 TNF IL17A IFNG HLA-B HLA-A

Graphical network of the top 20 diseases related to Uveitis:



Diseases related to Uveitis

Symptoms & Phenotypes for Uveitis

GenomeRNAi Phenotypes related to Uveitis according to GeneCards Suite gene sharing:

26 (show all 39)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-100 10.08 IL10
2 Increased shRNA abundance (Z-score > 2) GR00366-A-104 10.08 IL2RA
3 Increased shRNA abundance (Z-score > 2) GR00366-A-105 10.08 IFNA2
4 Increased shRNA abundance (Z-score > 2) GR00366-A-113 10.08 IL10
5 Increased shRNA abundance (Z-score > 2) GR00366-A-115 10.08 IL2RA
6 Increased shRNA abundance (Z-score > 2) GR00366-A-118 10.08 HLA-A HLA-B
7 Increased shRNA abundance (Z-score > 2) GR00366-A-121 10.08 IL2RA
8 Increased shRNA abundance (Z-score > 2) GR00366-A-124 10.08 IL1R1
9 Increased shRNA abundance (Z-score > 2) GR00366-A-125 10.08 IL10
10 Increased shRNA abundance (Z-score > 2) GR00366-A-127 10.08 IFNA2
11 Increased shRNA abundance (Z-score > 2) GR00366-A-130 10.08 IL2RA
12 Increased shRNA abundance (Z-score > 2) GR00366-A-138 10.08 IL2RA
13 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.08 IL10
14 Increased shRNA abundance (Z-score > 2) GR00366-A-161 10.08 IL10
15 Increased shRNA abundance (Z-score > 2) GR00366-A-167 10.08 IFNA2
16 Increased shRNA abundance (Z-score > 2) GR00366-A-168 10.08 IFNA2
17 Increased shRNA abundance (Z-score > 2) GR00366-A-174 10.08 IL2RA
18 Increased shRNA abundance (Z-score > 2) GR00366-A-183 10.08 IL1R1
19 Increased shRNA abundance (Z-score > 2) GR00366-A-184 10.08 IFNA2
20 Increased shRNA abundance (Z-score > 2) GR00366-A-198 10.08 IL10
21 Increased shRNA abundance (Z-score > 2) GR00366-A-202 10.08 IL2RA
22 Increased shRNA abundance (Z-score > 2) GR00366-A-210 10.08 NOD2 IL10
23 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.08 IL10
24 Increased shRNA abundance (Z-score > 2) GR00366-A-25 10.08 IL2RA IFNA2
25 Increased shRNA abundance (Z-score > 2) GR00366-A-29 10.08 IFNA2
26 Increased shRNA abundance (Z-score > 2) GR00366-A-34 10.08 IL2RA
27 Increased shRNA abundance (Z-score > 2) GR00366-A-36 10.08 NOD2
28 Increased shRNA abundance (Z-score > 2) GR00366-A-46 10.08 IL2RA
29 Increased shRNA abundance (Z-score > 2) GR00366-A-52 10.08 IL2RA IL10
30 Increased shRNA abundance (Z-score > 2) GR00366-A-53 10.08 IL10
31 Increased shRNA abundance (Z-score > 2) GR00366-A-62 10.08 IFNA2
32 Increased shRNA abundance (Z-score > 2) GR00366-A-65 10.08 IL10
33 Increased shRNA abundance (Z-score > 2) GR00366-A-67 10.08 IL2RA IL10
34 Increased shRNA abundance (Z-score > 2) GR00366-A-68 10.08 IL10
35 Increased shRNA abundance (Z-score > 2) GR00366-A-74 10.08 HLA-A HLA-B
36 Increased shRNA abundance (Z-score > 2) GR00366-A-82 10.08 IL10
37 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.08 IL10
38 Increased shRNA abundance (Z-score > 2) GR00366-A-9 10.08 IL1R1
39 Increased shRNA abundance (Z-score > 2) GR00366-A-99 10.08 IL1R1

MGI Mouse Phenotypes related to Uveitis:

45 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 10.28 CAPN5 CCL2 CTLA4 HLA-A ICAM1 IFNG
2 hematopoietic system MP:0005397 10.27 CTLA4 HLA-A ICAM1 IFNG IL10 IL17A
3 growth/size/body region MP:0005378 10.26 CAPN5 ICAM1 IFNG IL10 IL17A IL1R1
4 digestive/alimentary MP:0005381 10.25 CTLA4 ICAM1 IFNG IL10 IL17A IL1R1
5 homeostasis/metabolism MP:0005376 10.25 CTLA4 ICAM1 IFNG IL10 IL17A IL1R1
6 endocrine/exocrine gland MP:0005379 10.24 CTLA4 HLA-A ICAM1 IFNG IL10 IL17A
7 mortality/aging MP:0010768 10.21 CAPN5 CTLA4 HLA-A ICAM1 IFNG IL10
8 craniofacial MP:0005382 10.07 IFNG IL10 IL17A IL1R1 IL4 TGFB2
9 nervous system MP:0003631 10.06 HLA-A ICAM1 IFNG IL10 IL1R1 IL4
10 respiratory system MP:0005388 9.81 CTLA4 IFNG IL10 IL17A IL1R1 IL2RA
11 no phenotypic analysis MP:0003012 9.8 HLA-A IFNG IL10 IL17A IL4 TNF
12 skeleton MP:0005390 9.65 CTLA4 IFNG IL10 IL17A IL1R1 IL2RA
13 vision/eye MP:0005391 9.32 ICAM1 IFNG IL10 IL1R1 IL2RA IL4

Drugs & Therapeutics for Uveitis

Drugs for Uveitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 233)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
tannic acid Approved Phase 4 1401-55-4
2
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
3
Acetazolamide Approved, Vet_approved Phase 4 59-66-5 1986
4
Dorzolamide Approved Phase 4 120279-96-1 5284549 3154
5
Brinzolamide Approved Phase 4 138890-62-7 68844
6
Certolizumab pegol Approved Phase 4 428863-50-7
7
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
8
Loteprednol Approved, Experimental Phase 4 129260-79-3, 82034-46-6 9865442 444025
9
Latanoprost Approved, Investigational Phase 4 130209-82-4 5311221 5282380
10
Travoprost Approved Phase 4 157283-68-6 5282226
11
Timolol Approved Phase 4 26839-75-8 5478 33624
12
Bimatoprost Approved, Investigational Phase 4 155206-00-1 5311027
13
Tobramycin Approved, Investigational Phase 4 32986-56-4 36294 5496
14
Difluprednate Approved Phase 4 23674-86-4 443936
15
Abatacept Approved Phase 4 332348-12-6 10237
16
Ganciclovir Approved, Investigational Phase 4 82410-32-0 3454
17
Nepafenac Approved, Investigational Phase 4 78281-72-8 151075
18
Dipivefrin Approved Phase 4 52365-63-6 3105
19
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
20
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
21
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
22
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
23
Ranibizumab Approved Phase 4 347396-82-1 459903
24
Lactitol Approved, Investigational Phase 4 585-88-6, 585-86-4 493591
25
Tretinoin Approved, Investigational, Nutraceutical Phase 4 302-79-4 444795 5538
26
Choline Approved, Nutraceutical Phase 4 62-49-7 305
27
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 22737-96-8, 68-26-8, 11103-57-4 9904001 445354
28
Maleic acid Experimental, Investigational Phase 4 110-17-8, 110-16-7 444972
29
protease inhibitors Phase 4
30 HIV Protease Inhibitors Phase 4
31 Carbonic Anhydrase Inhibitors Phase 4
32 Adrenergic alpha-Agonists Phase 4
33 Adrenergic Agonists Phase 4
34 Brimonidine Tartrate Phase 4 70359-46-5
35 Cyclosporins Phase 4
36 Calcineurin Inhibitors Phase 4
37 Anticoagulants Phase 4
38 Cathartics Phase 4
39 Laxatives Phase 4
40 Adrenergic beta-Antagonists Phase 4
41 Antihypertensive Agents Phase 4
42 Adrenergic Agents Phase 4
43 Adrenergic Antagonists Phase 4
44 Dextrans Phase 4
45 Anti-Arrhythmia Agents Phase 4
46 Lubricant Eye Drops Phase 4
47 Plasma Substitutes Phase 4
48 Blood Substitutes Phase 4
49 Anti-Allergic Agents Phase 4
50 Carboxymethylcellulose Sodium Phase 4

Interventional clinical trials:

(show top 50) (show all 432)
# Name Status NCT ID Phase Drugs
1 A Multi-Center, Prospective Single Arm Study to Assess the Efficacy and Safety of RETISERT (Intravitreal Flucinolone Acetonide 0.59mg) in Patients With Refractory Ocular Behcet's Disease Unknown status NCT00720928 Phase 4 flucinolone acetonide
2 The Efficacy of Intravenous Pulses of Methylprednisolone in the Treatment of Patients With Ocular Involvement in Behcet's Disease, a Double Blind Pilot Study Unknown status NCT01306955 Phase 4 methylorednisolone
3 Effect of Prophylactic Aqueous Suppression on Hyperencapsulation of Ahmed Glaucoma Valves Unknown status NCT01535768 Phase 4 Aqueous Suppressant Eye Drops
4 Ozurdex Versus Ranibizumab Versus Combination for Central Retinal Vein Unknown status NCT01827722 Phase 4 Ozurdex;Ranibizumab;Combination Ozurdex with Ranibizumab PRN
5 Multicenter, Open-Label Study to Assess the Effects of Certolizumab Pegol on the Reduction of Anterior Uveitis Flares in Axial Spondyloarthritis Subjects With a History of Anterior Uveitis (C-VIEW) Completed NCT03020992 Phase 4 Certolizumab Pegol
6 Re-implantation of a Fluocinolone Acetonide Implant for Non-infectious Uveitis Affecting the Posterior Segment Completed NCT00543296 Phase 4 0.59 mg Fluocinolone Acetonide implant
7 TAHOE: Sustained InTravitreal DexAmetHasone Implant (Ozurdex) for Uveitic Macular Edema Completed NCT01870440 Phase 4 Ozurdex Intravitreal Injection (0.7 mg)
8 Prospective Open Label Study of H.P. Acthar Gel Injection in Patients With Active Non-Infectious Uveitis With Associated Glaucoma Thus High Frequency Regional Corticosteroid and Oral Corticosteroids Cause Intolerable Side-Effects Completed NCT02764697 Phase 4 H.P. ACTHAR SUBCUTANEOUS GEL INJECTION
9 Proof of Concept Study of the Effectiveness of Ozurdex in Lieu of Oral Corticosteroids for the Control of Active Intermediate and Posterior Uveitis Requiring Immunosuppressive Drug Therapy Completed NCT02049476 Phase 4 Dexamethasone pellet
10 Multi Center Prospective Registry of Infliximab Use for Childhood Uveitis Completed NCT00589628 Phase 4 infliximab;infliximab
11 Multicenter Uveitis Steroid Treatment (MUST) Trial Completed NCT00132691 Phase 4 fluocinolone acetonide intraocular implant;oral corticosteroid with immunosuppressive agents as needed
12 Multi-center, Randomized, Double Masked, Vehicle Controlled Phase IV Study to Compare the Efficacy, Ocular Safety and Tolerability of a Two Day Treatment With Eye Drops (0.5% Prednisolone Acetate, One Drop Four Times Per Day) in Patients With Intraocular Inflammation After Cataract Surgery, Followed by an Open Label Observational Period of 12 Days Completed NCT00170729 Phase 4 Prednisolone acetate
13 Blood-aqueous Barrier Changes After the Use of Timolol and Prostaglandin Analogues Fixed Combination in Pseudophakic Patients With Primary Open Angle Glaucoma Completed NCT01978015 Phase 4 travoprost and timolol maleate fixed combination;latanoprost and maleate timolol fixed combination;bimatoprost and timolol maleate fixed combination;dextran and hypromellose
14 Open-Label, Phase 4 Study, Investigating the Incidence of Extra-Articular Manifestations in Subjects With Ankylosing Spondylitis Treated With Golimumab; Protocol No. MK-8259-012 Completed NCT01668004 Phase 4
15 The Effects of BAK on the Blood Aqueous Barrier of Pseudophakic Patients Completed NCT01280110 Phase 4 Hydroxypropylmethylcellulose;Carboxymethylcellulose
16 A Randomized Clinical Trial Comparing the Intraocular Pressure Changes With the Use of Loteprednol and Dexamethasone After Pterygium Surgery Completed NCT00781300 Phase 4 Loteprednol Etabonate 0.5%;Dexamethasone 0.1%
17 Treatment of Dry Eye Using 0.03% Tacrolimus Eye Drops: Prospective Double-Blind Randomized Study Completed NCT01850979 Phase 4 Tacrolimus;Olive Oil
18 A Study to Investigate the Safety and Efficacy of Lucentis (Ranibizumab) in Patients With CNV Due to Causes Other Than AMD and in Patients Where Pigment Epithelial Detachments Are the Primary Manifestation of Their AMD. Completed NCT01628354 Phase 4 Ranibizumab
19 Prospective, Single-center, Six-month Study of Intravitreal Ranibizumab for Macular Edema With Nonproliferative Diabetic Retinopathy: Effects on Microaneurysm Turnover and Non-perfused Retinal Area Completed NCT02834663 Phase 4 Lucentis
20 Intravitreal Aflibercept (VEGF Trap-Eye) in Neovascular Age-related Macular Degeneration With Limited Response to Ranibizumab Completed NCT02309281 Phase 4 aflibercept 2mg
21 Citicoline Effect on Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) : Pattern Electroretinography Study Completed NCT03046693 Phase 4 Group A Citicoline 1000 mg oral tablet;Group B placebo oral tablet
22 Open-label, Single-center, Prospective Study on the Efficacy and Safety of Repository Corticotropin Injection (H.P. ACTHAR GEL) in the Treatment of Adults With Non-infectious Retinal Vasculitis Recruiting NCT03066869 Phase 4 H.P. ACTHAR GEL
23 Intra-cameral Penetration and Efficacy of Ganciclovir Following Topical Administration of 2% Ganciclovir Eye Drop for CMV Anterior Uveitis / Endotheliitis Recruiting NCT02943057 Phase 4 2% guttae ganciclovir
24 Macular Edema Nepafenac vs. Difluprednate Uveitis Trial Recruiting NCT01939691 Phase 4 Difluprednate;Nepafenac;Prednisolone acetate
25 Abatacept Bone Effects in Psoriatic Arthritis With Bone Biomarkers - ABEPSA _ BB Recruiting NCT04106804 Phase 4 Abatacept 125 MG/ML
26 A Clinical Trial of Infliximab for Injection in Refractory Childhood Uveitis Active, not recruiting NCT04150770 Phase 4 infliximab
27 Evaluation of DEXTENZA on the Management of Pain and Inflammation in Patients With Anterior Uveitis Compared to Standard of Care Topical Corticosteroids Not yet recruiting NCT04426734 Phase 4 Topical Prednisolone Acetate 1%
28 Subtenons Triamcinolone Acetonide Injections for Treatment of Persistent Choroidal Effusions Post Glaucoma Surgery Not yet recruiting NCT02917564 Phase 4 Triamcinolone Acetonide 1 ml of 40 mg/mL suspension
29 A Multicenter, Open Label Pilot Study to Explore the Efficacy and Safety of Acthar Gel in Subjects With Severe Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis (NIPPU) Suspended NCT03656692 Phase 4 Acthar Gel
30 Use of Thalidomide in Chronic Uveitis Terminated NCT00314665 Phase 4 Thalidomide
31 Corticosteroid Sparing Effect of Methotrexate in Patients With Sarcoid- Associated Uveitis: A Double Blind, Randomized, Placebo Controlled-study -UVEXATE Terminated NCT00918554 Phase 4 Methotrexate;Placebo
32 Prospective Open Label Study of Acthar SQ Gel Injection in Patients With Active Anterior Uveitis Who Are Not Well Controlled With, or Intolerant of, Topical or Systemic Corticosteroids Terminated NCT02769702 Phase 4 Acthar
33 Combination OZURDEX® & LUCENTIS® vs. OZURDEX® Monotherapy in Incomplete-Responders With Diabetic Macular Edema: The COLLIDE Trial Terminated NCT02684084 Phase 4 Ozurdex;Lucentis
34 Posterior Subtenon Versus Intravitreal Injection of Triamcinolone Acetonide for Treatment of Uveitic Cystoid Macular Edema (CME) Withdrawn NCT02598869 Phase 4 Triamcinolone Acetonide
35 Methotrexate in the Treatment of Axial Spondyloarthritis. A Randomized, Multicenter, Double-Blind, Placebo-Controlled Study. Withdrawn NCT00298012 Phase 4 Methotrexate
36 A Multi-center, Controlled, Safety and Efficacy Study of a Fluocinolone Acetonide Intravitreal (FAI) Insert in Subjects With Chronic Non-infectious Uveitis Affecting the Posterior Segment of the Eye Unknown status NCT02746991 Phase 3 Sham Injection;FAI Insert
37 Randomized Controlled Study to Evaluate the Efficacy of Adalimumab in Patients With Different Forms of Refractory Uveitis Acronym: Adalimumab in Uveitis Refractory to Conventional Therapy (ADUR Trial) Unknown status NCT00348153 Phase 2, Phase 3 Adalimumab
38 The Safety and Efficacy of a Tumor Necrosis Factor Receptor Fusion Protein on Uveitis Associated With Juvenile Rheumatoid Arthritis Unknown status NCT00012506 Phase 3 TNFR:Fc
39 Can Simvastatin Significantly Reduce the Amount of Immunosuppressive Medication Required by Patients With Sight Threatening Uveitis? A Phase 2b, Single Site, Randomized, Placebo Controlled, Double Blinded Trial. Unknown status NCT02252328 Phase 2, Phase 3 Simvastatin;Placebo
40 Phase III Study of Human Bone Marrow-Derived Mesenchymal Stem Cells to Treat AS Unknown status NCT02809781 Phase 2, Phase 3 Etanercept
41 Collaborative Ocular Melanoma Study (COMS) Unknown status NCT00000124 Phase 3
42 Open-label Safety Study of Suprachoroidal Triamcinolone Acetonide Injectable Suspension in Patients With Non-Infectious Uveitis Completed NCT03097315 Phase 3
43 Study of Difluprednate in the Treatment of Uveitis Completed NCT00501579 Phase 3 Difluprednate;Prednisolone Acetate
44 A Double-Masked, Placebo-Controlled, Multi-Center, Parallel-Group, Dose-Ranging Study With an Optional Extension to Assess the Efficacy and Safety of LX211 as Therapy in Subjects With Clinically Quiescent Sight Threatening, Non-infectious Intermediate, Anterior and Intermediate, Posterior or Pan-Uveitis Completed NCT00404742 Phase 3 Placebo;LX211;LX211;LX211
45 A Double-Masked, Placebo-Controlled, Parallel Group, Multi-Center, Dose-Ranging Study With an Optional Extension to Assess the Efficacy and Safety of LX211 as Therapy in Subjects With Active Sight Threatening, Non-infectious Intermediate-, Anterior and Intermediate-, Posterior-, or Pan-Uveitis Completed NCT00404612 Phase 3 Placebo;LX211;LX211;LX211
46 Phase 3 Confirmatory Study of 0.05% Difluprednate Ophthalmic Emulsion in the Treatment of Anterior Uveitis (Including Panuveitis). Completed NCT00406887 Phase 3 Difluprednate Ophthalmic Emulsion
47 A Double-Masked, Placebo-Controlled, Parallel-Group, Multi-Center, Dose-Ranging Study With an Optional Extension to Assess the Efficacy and Safety of LX211 as Therapy in Subjects With Active Sight Threatening, Non-infectious Anterior Uveitis Completed NCT00404885 Phase 3 Placebo;LX211;LX211;LX211
48 A Study of the Safety and Efficacy of a New Treatment for Non-Infectious Intermediate or Posterior Uveitis Completed NCT00333814 Phase 2, Phase 3 Dexamethasone;dexamethasone;Sham injection
49 A Phase 3, Randomized, Masked, Controlled Clinical Trial to Study the Safety and Efficacy of Triamcinolone Acetonide Injectable Suspension (CLS-TA) for the Treatment of Subjects With Macular Edema Associated With Non-infectious Uveitis Completed NCT02595398 Phase 3 4mg CLS-TA Suprachoriodal Injection;Sham Procedure
50 A Multicenter Open-Label Study of the Long-term Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Non-infectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis Completed NCT01148225 Phase 3 adalimumab

Search NIH Clinical Center for Uveitis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Atropine
Atropine Sulfate
Methylatropine nitrate

Cochrane evidence based reviews: uveitis

Genetic Tests for Uveitis

Genetic tests related to Uveitis:

# Genetic test Affiliating Genes
1 Uveitis 29

Anatomical Context for Uveitis

MalaCards organs/tissues related to Uveitis:

40
Eye, T Cells, Endothelial, Retina, Testes, Skin, Bone

Publications for Uveitis

Articles related to Uveitis:

(show top 50) (show all 17802)
# Title Authors PMID Year
1
Immune responses to interphotoreceptor retinoid-binding protein and S-antigen in Behcet's patients with uveitis. 54 61
20089879 2010
2
Successful resolution of pneumonia developed in a patient affected by Crohn's disease, rheumatoid arthritis, myasthenia gravis and recurrent uveitis during concomitant treatment with tumour necrosis factor alpha inhibitors and conventional immunosuppressive drugs. 61 54
19551384 2010
3
Production of interleukin-17 in Behcet's disease is inhibited by cyclosporin A. 54 61
20508866 2010
4
Infliximab and anterior optic neuropathy: case report and review of the literature. 54 61
19916016 2010
5
Efficacy of infliximab on the acute attack of uveitis. 54 61
20062906 2010
6
Intravitreal infliximab in experimental endotoxin-induced uveitis. 54 61
19787603 2009
7
Suppression of experimental uveitis by a recombinant adeno-associated virus vector encoding interleukin-1 receptor antagonist. 61 54
19693263 2009
8
Immune response genes in uveitis. 61 54
19657978 2009
9
Diagnosis of tuberculous uveitis: clinical application of an interferon-gamma release assay. 61 54
19576501 2009
10
Cytokine and molecular analyses of intraocular lymphoma. 61 54
19585355 2009
11
Inhibitory effect of Cyclosporin A and corticosteroids on the production of IFN-gamma and IL-17 by T cells in Vogt-Koyanagi-Harada syndrome. 61 54
19200788 2009
12
Retinal S-antigen Th1 cell epitope mapping in patients with Behcet's disease. 61 54
18958488 2009
13
Nucleotide oligomerization domain-2 (NOD2)-induced uveitis: dependence on IFN-gamma. 54 61
19098321 2009
14
Cytokine profiles in toxoplasmic and viral uveitis. 61 54
19302012 2009
15
[Recommendations for tuberculosis screening before and during treatment with tumour necrosis factor inhibitors]. 54 61
19459572 2009
16
Anti-inflammatory role of IL-17 in experimental autoimmune uveitis. 54 61
19234216 2009
17
Serum PEDF levels are decreased in a spontaneous animal model for human autoimmune uveitis. 61 54
19113885 2009
18
Blau syndrome-related CARD15/NOD2 mutations are not linked to idiopathic uveitis in Spanish patients. 54 61
19822951 2009
19
Developments in the scientific and clinical understanding of the spondyloarthritides. 54 61
19232062 2009
20
Interphotoreceptor retinoid-binding protein as biomarker in systemic autoimmunity with eye inflictions. 61 54
18266969 2008
21
Retrospective analysis of children with uveitis treated with infliximab. 54 61
18930672 2008
22
Evidence for endotoxin as a causative factor for leptospiral uveitis in humans. 54 61
18658094 2008
23
Long-term efficacy and safety of low-dose interferon alpha2a therapy in severe uveitis associated with Behçet disease. 54 61
19027420 2008
24
TNFalpha-blocking agents or conventional immunosuppressive drugs in the therapy of children with uveitis? - an evidence based approach. 61 54
18949668 2008
25
Lentiviral-vector-mediated expression of murine IL-1 receptor antagonist or IL-10 reduces the severity of endotoxin-induced uveitis. 54 61
18580969 2008
26
[Recent advances in studies of clinical treatment of uveitis]. 61 54
19176129 2008
27
Interferon-gamma release assays in the diagnosis of tuberculous uveitis. 61 54
18804561 2008
28
High-dose humanized anti-IL-2 receptor alpha antibody (daclizumab) for the treatment of active, non-infectious uveitis. 54 61
18571896 2008
29
Update on biologics in juvenile idiopathic arthritis. 61 54
18698187 2008
30
Spotlight on anti-CD25: daclizumab in MS. 61 54
18808743 2008
31
Regression of vasoproliferative tumor with systemic infliximab. 61 54
18717448 2008
32
Upregulated IL-23 and IL-17 in Behçet patients with active uveitis. 54 61
18579762 2008
33
Mutation screening of the CARD15 gene in sarcoidosis. 54 61
18384487 2008
34
The use of infliximab in ocular inflammation. 54 61
18408083 2008
35
Tumor necrosis factor inhibitors and uveitis: comment on the article by Lim et al. 61 54
18438832 2008
36
Link between tumor necrosis factor inhibitors and onset of uveitis: comment on the article by Lim et al. 54 61
18438831 2008
37
Uveitis following the use of tumor necrosis factor alpha inhibitors: comment on the article by Lim et al. 61 54
18438848 2008
38
NOD2, the gene responsible for familial granulomatous uveitis, in a mouse model of uveitis. 54 61
18385071 2008
39
Interferon-gamma assay in tuberculous uveitis. 54 61
18369081 2008
40
Antigen-dependent monophasic or recurrent autoimmune uveitis in rats. 54 61
18203685 2008
41
[Association of ocular inflammation and innate immune response]. 61 54
18411715 2008
42
Th1 and Th2 responses on the ocular surface in uveitis identified by CCR4 and CCR5 conjunctival expression. 61 54
18222196 2008
43
A case report: zoledronic acid-induced anterior uveitis. 61 54
18488162 2008
44
Labrafil--a new adjuvant for peptide-specific oral tolerance in rat experimental autoimmune uveitis. 61 54
18042397 2008
45
TNFalpha blockade in human diseases: an overview of efficacy and safety. 54 61
17916445 2008
46
Cytokine profile in Behçet uveitis. 61 54
19348376 2008
47
[Profile of selected cytokines in various forms of uveitis]. 54 61
19112859 2008
48
Analysis of Crohn's disease-related CARD15 polymorphisms in Spanish patients with idiopathic uveitis. 54 61
18219096 2008
49
Equine recurrent uveitis--a spontaneous horse model of uveitis. 54 61
18421230 2008
50
Aqueous humor levels of asymmetric dimethylarginine (ADMA) are positively associated with monocyte chemoattractant protein-1 (MCP-1) in patients with uveitis. 54 61
17591667 2008

Variations for Uveitis

Expression for Uveitis

Search GEO for disease gene expression data for Uveitis.

Pathways for Uveitis

Pathways related to Uveitis according to GeneCards Suite gene sharing:

(show top 50) (show all 67)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.08 TNF NOD2 IL4 IL2RA IL1R1 IL17A
2
Show member pathways
13.86 TNF TGFB2 IL4 IL2RA IL1R1 IL17A
3
Show member pathways
13.74 TNF TGFB2 IL4 IL2RA IL1R1 IL17A
4
Show member pathways
13.6 TNF TGFB2 IL4 IL2RA IL1R1 IL17A
5
Show member pathways
13.46 TNF TGFB2 IL4 IL2RA IL1R1 IL17A
6
Show member pathways
13.36 TNF TGFB2 IL4 IL2RA IL1R1 IL17A
7
Show member pathways
13.18 TNF NOD2 IL4 IL2RA IL1R1 IL17A
8
Show member pathways
13.09 TNF TGFB2 IL10 IFNG IFNA2 CCL2
9
Show member pathways
13.03 TNF IL4 IL2RA IFNA2 HLA-B HLA-A
10
Show member pathways
13 TNF IL1R1 IFNA2 ICAM1 HLA-B HLA-A
11
Show member pathways
12.87 TNF IL2RA IFNG IFNA2 ICAM1 HLA-B
12 12.86 TGFB2 IL4 IL2RA IFNG IFNA2
13 12.86 TNF IFNG IFNA2 HLA-B HLA-A CCL2
14
Show member pathways
12.68 TNF IL4 IL2RA IL10 IFNG
15
Show member pathways
12.67 TNF IL4 IL17A IL10 IFNG CTLA4
16
Show member pathways
12.64 TNF IL17A IL10 IFNG CCL2
17
Show member pathways
12.62 TNF TGFB2 NOD2 IL4 IL2RA IL1R1
18
Show member pathways
12.6 IFNG IFNA2 ICAM1 HLA-B HLA-A
19
Show member pathways
12.57 TNF IL4 IFNG IFNA2 ICAM1 HLA-B
20 12.54 TRIB2 TNF IL4 IL2RA IL17A IL10
21
Show member pathways
12.51 IL4 IL2RA IL10 IFNG IFNA2
22
Show member pathways
12.41 TNF IL4 IL17A IFNG CCL2
23
Show member pathways
12.4 TNF IL4 IFNG ICAM1 CCL2
24 12.38 TNF TGFB2 IL2RA IL1R1 ICAM1 HLA-B
25
Show member pathways
12.37 TNF IL2RA IL10 CCL2
26
Show member pathways
12.34 TNF TGFB2 IL4 IL10 IFNG
27 12.31 TNF TGFB2 NOD2 IL10 IFNG IFNA2
28 12.28 TNF NOD2 IFNA2 CCL2
29
Show member pathways
12.24 TNF IL4 IL1R1 IFNG
30 12.19 TNF IL1R1 IFNG ICAM1 CCL2
31 12.18 ICAM1 HLA-B HLA-A CTLA4
32 12.11 TNF TGFB2 IL1R1 IFNG
33
Show member pathways
12.11 TNF IL4 IL2RA IL17A IL10 IFNG
34 12.09 TNF IL4 IL1R1 IFNG ICAM1 CCL2
35
Show member pathways
12.08 IL4 IL2RA IL1R1 IFNG HLA-A
36 12.07 TNF IL4 IL2RA IL10 IFNG IFNA2
37 12.05 TNF NOD2 ICAM1 CCL2
38 12.04 TNF IL4 IL17A IL10 ICAM1 CCL2
39
Show member pathways
12.02 TNF IL17A IL10 IFNG
40 12.02 TNF TGFB2 IL1R1 IL10 IFNG
41 11.98 TNF TGFB2 ICAM1 CCL2
42 11.98 TNF IL4 IL2RA IL1R1
43
Show member pathways
11.96 TGFB2 IL4 IL1R1 IL17A IFNG
44
Show member pathways
11.86 TNF TGFB2 IL4 IL2RA IL17A IL10
45
Show member pathways
11.85 TNF IL4 IL2RA IFNG CTLA4
46 11.84 TNF IL10 IFNG IFNA2
47 11.83 IL4 IFNG ICAM1
48 11.83 TNF TGFB2 IL17A IFNG ICAM1 CTLA4
49
Show member pathways
11.74 TNF IL2RA IFNG HLA-A
50
Show member pathways
11.7 TNF IFNG ICAM1

GO Terms for Uveitis

Cellular components related to Uveitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.96 TNF TGFB2 RBP3 IL4 IL1R1 IL17A
2 extracellular space GO:0005615 9.65 TNF TGFB2 RBP3 IL4 IL17A IL10
3 external side of plasma membrane GO:0009897 9.63 TNF IL2RA IL1R1 IL17A ICAM1 CTLA4
4 MHC class I protein complex GO:0042612 9.32 HLA-B HLA-A
5 cell surface GO:0009986 9.23 TNF NOD2 IL2RA IL1R1 ICAM1 HLA-B

Biological processes related to Uveitis according to GeneCards Suite gene sharing:

(show top 50) (show all 54)
# Name GO ID Score Top Affiliating Genes
1 adaptive immune response GO:0002250 10.1 IFNG IFNA2 HLA-B HLA-A CTLA4
2 regulation of immune response GO:0050776 10.01 IL4 ICAM1 HLA-B HLA-A
3 inflammatory response GO:0006954 10.01 TNF IL2RA IL1R1 IL17A IFNA2 CCL2
4 positive regulation of ERK1 and ERK2 cascade GO:0070374 10 TNF NOD2 ICAM1 CCL2
5 defense response GO:0006952 9.95 TNF NOD2 IFNA2 HLA-B
6 cellular response to interleukin-1 GO:0071347 9.89 IL17A ICAM1 CCL2
7 B cell differentiation GO:0030183 9.89 IL4 IL10 IFNA2
8 cellular response to organic cyclic compound GO:0071407 9.88 TNF NOD2 CCL2
9 cellular response to lipopolysaccharide GO:0071222 9.88 TNF NOD2 IL10 ICAM1 CCL2
10 type I interferon signaling pathway GO:0060337 9.87 IFNA2 HLA-B HLA-A
11 positive regulation of interferon-gamma production GO:0032729 9.83 TNF IL1R1 HLA-A
12 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.83 TNF IL4 IFNG IFNA2
13 extrinsic apoptotic signaling pathway GO:0097191 9.82 TNF TGFB2 IFNG
14 positive regulation of nitric oxide biosynthetic process GO:0045429 9.82 TNF IFNG ICAM1
15 negative regulation of T cell proliferation GO:0042130 9.81 IL2RA IL10 CTLA4
16 positive regulation of interleukin-6 secretion GO:2000778 9.81 TNF IL17A IFNG
17 interferon-gamma-mediated signaling pathway GO:0060333 9.81 IFNG ICAM1 HLA-B HLA-A
18 positive regulation of pri-miRNA transcription by RNA polymerase II GO:1902895 9.8 TNF TGFB2 IL10
19 cell surface receptor signaling pathway GO:0007166 9.8 SAG IL2RA IL1R1 IFNG IFNA2 CCL2
20 negative regulation of endothelial cell apoptotic process GO:2000352 9.79 IL4 IL10 ICAM1
21 positive regulation of cytokine secretion GO:0050715 9.77 TNF IL10 IFNG
22 microglial cell activation GO:0001774 9.76 TNF IL4 IFNG
23 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.73 TNF NOD2 IL17A
24 positive regulation of osteoclast differentiation GO:0045672 9.72 TNF IL17A IFNG
25 negative regulation of tumor necrosis factor biosynthetic process GO:0042536 9.71 IL4 IL10
26 negative regulation of amyloid-beta clearance GO:1900222 9.71 TNF IFNG
27 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independent GO:0002480 9.71 HLA-B HLA-A
28 humoral immune response GO:0006959 9.71 TNF IFNG IFNA2 CCL2
29 endothelial cell apoptotic process GO:0072577 9.69 TNF IL10
30 antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independent GO:0002486 9.69 HLA-B HLA-A
31 positive regulation of NMDA glutamate receptor activity GO:1904783 9.69 IFNG CCL2
32 regulation of complement-dependent cytotoxicity GO:1903659 9.68 TGFB2 IL10
33 positive regulation of mononuclear cell migration GO:0071677 9.68 TNF IL4
34 protection from natural killer cell mediated cytotoxicity GO:0042270 9.68 HLA-B HLA-A
35 type 2 immune response GO:0042092 9.68 IL4 IL10
36 negative regulation of cytokine production involved in immune response GO:0002719 9.67 TNF IL10
37 positive regulation of cellular respiration GO:1901857 9.67 IL4 IFNG
38 neuroinflammatory response GO:0150076 9.67 IL4 IFNG
39 regulation of regulatory T cell differentiation GO:0045589 9.67 IL2RA IFNG CTLA4
40 positive regulation of interleukin-23 production GO:0032747 9.66 IL17A IFNG
41 negative regulation of cytokine secretion involved in immune response GO:0002740 9.66 TNF IL10
42 regulation of isotype switching GO:0045191 9.63 IL4 IL10
43 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 9.63 NOD2 IFNG CCL2
44 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.61 TNF IFNG
45 receptor biosynthetic process GO:0032800 9.61 TNF IL10
46 positive regulation of chemokine biosynthetic process GO:0045080 9.61 TNF IL4 IFNG
47 cytokine-mediated signaling pathway GO:0019221 9.61 TNF IL4 IL2RA IL1R1 IL17A IL10
48 negative regulation of alkaline phosphatase activity GO:0010693 9.6 TNF TGFB2
49 positive regulation of vitamin D biosynthetic process GO:0060557 9.58 TNF IFNG
50 positive regulation of nitrogen compound metabolic process GO:0051173 9.57 TNF IFNG

Molecular functions related to Uveitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.23 TNF TGFB2 IL4 IL17A IL10 IFNG
2 TAP binding GO:0046977 8.96 HLA-B HLA-A

Sources for Uveitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....